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0163-7258/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 8 August 2016 Acid-related diseases (ARDs), such as peptic ulcers and gastroesophageal reﬂux disease, represent a major
health-care concern. Some major milestones in our understanding of gastric acid secretion and ARD treatment
reached during the last 50 years include 1) discovery of histamine H2-receptors and development of H2-
receptor antagonists, 2) identiﬁcation ofH+,K+-ATPase as the parietal cell protonpump and development of pro-
ton pump inhibitors (PPIs), and 3) identiﬁcation of Helicobacter pylori (H. pylori) as the major cause of peptic ul-
cers and development of effective eradication regimens. Although PPI treatments have been effective and
successful, there are limitations to their efﬁcacy and usage, i.e. short half-life, insufﬁcient acid suppression,
slow onset of action, and large variation in efﬁcacy among patients due to CYP2C19 metabolism. Potassium-
competitive acid blockers (P-CABs) inhibit H+,K+-ATPase in a reversible andK+-competitivemanner, and exhib-
it almost complete inhibition of gastric acid secretion from the ﬁrst dose. Many pharmaceutical companies have
tried to develop P-CABs, butmost of their clinical development has been discontinued due to safety concerns or a
similar efﬁcacy to PPIs. Revaprazan was developed in Korea and was the ﬁrst P-CAB approved for sale.
Vonoprazan, approved in 2014 in Japan, has a completely different chemical structure and higher pKa value com-
pared to other P-CABs, and exhibits rapid onset of action and prolonged control of intragastric acidity.
Vonoprazan is an effective treatment for ARDs that is especially effective in healing reﬂux esophagitis and for
H. pylori eradication. P-CABs, such as vonoprazan, promise to further improve the management of ARDs.







Proton pump inhibitor1. Introduction
Gastric acid is important for the sterilization of food and water and
for digestion. Gastric acid secretion is a complex process that involves
neuronal, hormonal, and endocrine pathways, all of which have one
common target: the parietal cell. The parietal cell is responsible for
secreting concentrated hydrochloric acid into the gastric lumen. The
empirical realization that peptic ulcer disease (PUD) only occurred in
the presence of gastric acid (Schwartz, 1900) led to the dictum of “no
acid, no ulcer”. Acid is also considered of central importance in the
initiation and continuation of gastroesophageal reﬂux disease (GERD),
nonsteroidal anti-inﬂammatory drug (NSAID) associated upper gastro-
intestinal damage, and ulceration in hypersecretory conditions such as
Zollinger–Ellison syndrome. Many patients with these diseases beneﬁtcystokinin-2 receptor; ECL, en-
ist;H. pylori,Helicobacter pylori;
3 receptor; P-CAB, potassium-
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. This is an open access article underfrom acid-suppressive therapy, supporting the importance of gastric
acid in the pathogenesis of these diseases.
Since the isolation of Helicobacter pylori (H. pylori) more than
30 years ago (Marshall &Warren, 1984), our understanding of the path-
ogenesis of gastroduodenal diseases has changed dramatically. Many
diseases related toH. pylori, such as peptic ulcer andmucosal associated
lymphoid tissue lymphoma, are curable, and gastric cancer might even
be preventable, by the implementation of H. pylori eradication therapy
(Malfertheiner et al., 2014). The incidence of PUD in theWestern hemi-
sphere and Japan has decreased in the past fewdecades, probably due to
decreased infection rates withH. pylori. However, over the same period,
the incidence of GERD has increased dramatically andGERDhas become
a major gastric acid-related disease (ARD).
The healing of duodenal ulcers, gastric ulcers and GERD with acid
suppressants is highly correlated with control of gastric acid secretion
(Burget et al., 1990; Howden et al., 1991; Bell et al., 1992). The goals
of treatment for these diseases are to heal established lesions, relieve
symptoms, and to prevent recurrence and complications. A meta-
analysis has shown that maintaining intragastric pH at 3 or above for
18 to 20 h a day is optimal for healing duodenal ulcer (Howden et al.,





Fig. 1. The catalytic cycle of gastric H+,K+-ATPase.
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1999). Current H. pylori eradication therapy uses at least 2 antibiotics,
such as amoxicillin and clarithromycin, and also requires administration
of acid suppressant to elevate intragastric pH to 5 or above to promote
H. pylori transition from a stationary phase to a growth phase, which
leaves the bacteria susceptible to antibiotics (Sachs et al., 2011). The
quest for better therapies has pushed research towards new acid-
suppressive agents and formulations (Scarpignato & Hunt, 2015).
This review examines the development and issues associated with cur-
rent ARD treatments, with a particular focus placed on potassium-
competitive acid blockers (P-CABs) which promise to be themost effec-
tive acid suppressant to date.
2. Mechanisms of gastric acid secretion
The parietal cell of the gastric gland is a highly differentiated cell re-
sponsible for secreting concentrated hydrochloric acid into the gastric
lumen. Gastric acid secretion can occur upon ingestion of food or
drink, or be stimulated by the thought, smell, or taste of food. Such
direct and indirect parietal cell stimulation is mediated by 3 types of
receptor: cholinergic muscarinic M3 receptors (M3R), histamine H2-
receptors (H2R), and cholecystokinin-2/gastrin receptors (CCK2R). His-
tamine, produced in enterochromafﬁn-like (ECL) cells by the decarbox-
ylation of L-histidine by histidine decarboxylase, is thought to play a
central role as a stimulant of gastric acid secretion by binding to H2R.
H2R activation causes an increase in intracellular cyclic AMP levels,
which serves as a second messenger that transfers the signal to the
ﬁnal step of acid secretion, i.e. H+,K+-ATPase (Ganser & Forte, 1973;
Soll &Wollin, 1979). In contrast, stimulation of eitherM3R by acetylcho-
line or CCK2R by gastrin results in a signal mediated by an intracellular
increase in free Ca2+ ions. Gastrin mediates acid secretion primarily
by stimulating the release of histamine from neuroendocrine ECL cells
after binding to CCK2R. There has been some debate over whether acti-
vation of the parietal cell CCK2R leads to acid secretion (Hinkle et al.,
2003; Dufresne et al., 2006), and it seems the intracellular concentration
of cyclic AMPmust ﬁrst be above a threshold level before gastrin can di-
rectly stimulate the parietal cell (Soll, 1982; Geibel et al., 1995). Activa-
tion of these receptors stimulates H+,K+-ATPase (Sachs et al., 2014).
H+,K+-ATPase belongs to the family of P2-type ATPases, which in-
cludes the ubiquitous Na+,K+-ATPase and sarcoplasmic reticulum
Ca2+-ATPase. H+,K+-ATPase assembles as a heterodimer comprised of
one catalytic α and one β subunit, which share a signiﬁcant degree of
sequence homology with the corresponding subunits of Na+,K+-
ATPase. The H+,K+-ATPase α subunit contains about 1035 amino
acids (Maeda et al., 1988) and the β subunit contains about 290 amino
acids (Hall et al., 1990; Reuben et al., 1990). The H+,K+-ATPase α sub-
unit has 10 transmembrane segments and the β subunit has 1 trans-
membrane segment. The α subunit contains the catalytic site and is
responsible for ion exchange between the gland lumen and parietal
cell cytosol, while theβ subunit is essential for stabilization of theα sub-
unit. The extracellular domain of the β subunit contains multiple N-
glycosylation sites,which are not only necessary for targetedmembrane
trafﬁcking, but also for correct heterodimer assembly (Asano et al.,
2000; Vagin et al., 2003). In the resting parietal cell, H+,K+-ATPase is
found in smooth-surfaced cytoplasmic tubulovesicles. Upon stimula-
tion, H+,K+-ATPase is moved to apical microvilli of the secretory cana-
liculi of the parietal cell (Yao & Forte, 2003; Forte & Zhu, 2010). Along
with H+,K+-ATPase, the K+-channel KCNQ1/KCNE2 complex and a
Cl− channel are also moved (Lambrecht et al., 2005; Nguyen et al.,
2013). This morphological change results in a several-fold expansion
of the secretory canaliculi (Helander & Hirschowitz, 1972). H+,K+-
ATPase catalyzes an electroneutral exchange of cytoplasmic protons
for extracytoplasmic potassium by means of conformational changes
that occur by MgATP-driven phosphorylation and dephosphorylation
of the α subunit (Sachs et al., 1976). Activation of K+ and perhaps Cl−
conductance in the H+,K+-ATPase membrane allows K+ to access theextracytoplasmic face of the pump, which enables dephosphorylation
and recycling of the pump (Wolosin & Forte, 1983). H+,K+-ATPase con-
formations that bind ions for outward transport are termed E1 confor-
mations, and conformations that bind luminal ions for inward
transport are termed E2 conformations. As a member of the P2-type
ATPase family, the H+,K+-ATPase enzyme cycle involves switching
between E1 and E2-P states (Fig. 1). Hydronium ion binding to the cyto-
plasmic surface of the E1 form of H+,K+-ATPase activates phosphoryla-
tion by MgATP to form the intermediate E1-P, which then converts to
E2-P in the acid transporting step. After release of H3O+ and binding
of K+ on the extracytoplasmic surface of the enzyme, the E2-PK+ con-
formation is formed. The E2-PK+ conformation then converts to the
E1K+ conformation after dephosphorylation. The E1K+ conformation
releases K+ to the cytoplasmic side, allowing rebinding of H3O+ and
completing the enzyme cycle. At neutral pH, 2H+ are exchanged for
2 K+ per hydrolysis of 1 ATP, but as the luminal pH falls, the exchange
stoichiometry becomes 1H+ exchanged for 1K+ per 1 ATP. This stoichi-
ometry change is explained by the pKa of one of the hydroniumbinding
sites, which remains protonated at luminal pH b3.0 (Rabon et al., 1982).
H+,K+-ATPase exists as an (αβ)2 heterodimeric dimer (Shin & Sachs,
2006).
When active acid secretion ceases, parietal cells revert to a resting
conformation to prepare for the next stimulation (Forte et al., 1977).
Based on the membrane recruitment and recycling hypothesis, with-
drawal of stimulus leads to a progressive resequestration of the expand-
ed apical membrane and H+,K+-ATPase is taken back into the
cytoplasmic tubulovesicles. The proton pump protein has a half-life of
about 54 h in rats (and probably similar in humans), thus about 20%
of pumps are synthesized anew over 24 h (Shin & Kim, 2013).
It has been suggested that gastric H+,K+-ATPase is present at sites
other than the stomach e.g., the cortical collecting duct of the kidney
(Kraut et al., 2001), rat vascular smooth muscle cells (McCabe &
Young, 1992), human leukocytes (Ritter et al., 1998), and rat cardiac
myocytes (Beisvag et al., 2003). However, Herrmann et al. (2007) clear-
ly demonstrated, using quantitative mRNA analysis, western blot, and
immunohistochemistry, that the stomach is the only organ in humans
that expresses signiﬁcant levels of mRNA and protein of both the α-
and β-subunits of gastric H+,K+-ATPase.
3. Antacids and receptor antagonists
Pharmacotherapy for PUD has comprised largely ineffective ap-
proaches that included antacids and anticholinergics. Antacids, such as
sodium bicarbonate, aluminum hydroxide, magnesium hydroxide and
calcium carbonate, have come into widespread use, especially in associ-
ationwith a strict Sippy-type bland diet (Sippy, 1983). Antacids provide
a degree of symptom relief by neutralizing intragastric acid, but their
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1975). Anticholinergic agents (non-selective muscarinic receptor an-
tagonists) were also put to limited use since they were relatively weak
inhibitors at therapeutic doses and had many side effects such as dry
mouth, blurred vision, tachycardia, and bladder dysfunction (Mejia &
Kraft, 2009). Currently, no selective M3 antagonists are available for
clinical use. Selective M1R antagonists, such as pirenzepine and
telenzepine, have beenused clinically since their side effects are less fre-
quent. Although pirenzepine produces slight inhibition of basal, stress,
andmeal-stimulated acid secretion at doses of 50 to 100mg, H2R antag-
onists (H2RAs) inhibit acid secretion more effectively than pirenzepine
(Fiorucci et al., 1988). Pirenzepine also inhibits muscarinic receptors
outside the stomach, causing side effects such as drymouth and blurred
vision at higher doses. Ash and Schild (1966) clearly demonstrated that
histamine receptors expressed in the stomach or uterus are different
from those in the ileum, and concluded that at least two classes of hista-
mine receptors exist. Black et al. (1972) of Smith, Kline & French (now
GlaxoSmithKline) succeeded in developing burimamide, the ﬁrst
H2RA. Burimamide was not potent enough for oral administration, and
structural modiﬁcations intended to change the acid dissociation con-
stant of burimamide, led to the development of metiamide. Metiamide
was an effective agent, but was associated with unacceptable nephro-
toxicity and agranulocytosis. It was proposed that this toxicity arose
due to the thiourea group inmetiamide, and so other, similar guanidine
analogs were investigated. This led to the discovery of cimetidine, the
ﬁrst clinically successful H2RA (Brimblecombe et al., 1975). Cimetidine
was approved in 1976 in the UK and in 1977 in the USA. By modifying
the chemical structure of cimetidine, Glaxo (also nowGlaxoSmithKline)
developed ranitidine and Yamanouchi (now Astellas Pharma) devel-
oped famotidine. Ranitidine and famotidine were found to have a far-
improved tolerability proﬁle (i.e. fewer adverse drug reactions),
longer-lasting action, and be more potent than cimetidine. The discov-
ery of H2RAs revolutionized PUD therapy. H2RAs offer several advan-
tages over antacids, including longer duration of action, greater
efﬁcacy, and the ability to be used prophylactically as well as for symp-
tom relief. However, several shortcomings of H2RAs became apparent.
Firstly, because of their limited duration of action, patients needed to
take 2 or 3 doses each day. Secondly, H2RAs induce tachyphylaxis/toler-
ance after several days of treatment. Thirdly, their effect on meal-
stimulated acid secretion is limited as compared to their effect on
basal acid secretion at night. Furthermore, their efﬁcacy in relieving
GERD symptoms and eradicating H. pylori is mostly inadequate (Sachs
et al., 2014).
Several high afﬁnity CCK2R antagonists, such as YM-022 (Nishida
et al., 1994), RP-73870 (Pendley et al., 1995), S-0509 (Takeuchi et al.,
1999), YF-476 (Takinami et al., 1997) and spiroglumide (Scarpignato
et al., 1996) have been evaluated and shown to reduce gastric acid se-
cretion. YF-476, the gold standard of this class, inhibited gastric acid se-
cretion for longer than ranitidine (Boyce et al., 2012). However, the
development of this compound was stopped after its ability to inhibit
acid secretion was found to decline over several days (Steel, 2002).
The development of other compounds was also suspended.
4. Proton pump inhibitors
The French pharmaceutical company Servier reported strong
antisecretory activities for thioacetamide derivatives (coded by Servier
as CMN 131; Malen & Danree, 1971), but development of these com-
pounds was not pursued as they produced strong acute toxicity in ani-
mals. The antisecretory activity of CMN 131 prompted AB Hässle to
start looking for structural analogs that did not cause acute toxicity. Sci-
entists at AB Hässle speculated that the toxicity might originate from a
thioamide group, so they eliminated the thioamide group and added a
benzimidazole ring. Finally, a sulﬁde was modiﬁed to a sulfoxide due
to a conﬂicting preexisting patent, and timoprazole was synthetized
(Olbe et al., 2003). Subsequent toxicological studies of timoprazolerevealed that it caused enlargement of the thyroid gland. Other deriva-
tives were screened and picoprazole was found to have strong
antisecretory activity without the toxicological effects of timoprazole
seen in the thyroid/thymus. Scientists at AB Hässle also found that
picoprazole, unlike H2RAs, inhibited acid secretion independently of
stimulus. This effect was thought to be due to inhibition of H+,K+-
ATPase, indicating that picoprazole was a new class of antisecretory
compound (Fellenius et al., 1981). Binding studies with substituted
benzimidazoles showed that speciﬁc binding to H+,K+-ATPase oc-
curred in the secretory canaliculi of parietal cells. Substituents on the
heterocyclic ring were modiﬁed and a compound was obtained with a
weak base at the site of action. This compound, synthetized in 1979,
was given the generic name of omeprazole, and was developed as the
world's ﬁrst PPI (Lundell, 2015).
In the late 1960s, Takeda Pharmaceuticals also discovered that 2-
pyridylthioacetamide (coded by Takeda as AG-35) and its analogs ex-
hibited a strong antisecretory and antiulcer activity in animals during
screening for antiulcer drugs (Kanno et al., 1973), and the company
applied for a Japanese patent for the compounds as novel antiulcer
drugs (Kanai et al., 1969). AB Hässle's ﬁndings regarding novel mecha-
nisms of antisecretory actionmotivated Takeda to screen for antisecretory
drugs. Takeda screened more than 700 compounds in searching for a
new acid suppressant with a chemical structure that differed from
timoprazole, but eventually recognized the basic structure of timoprazole
was essential (Satoh, 2013). Takeda investigated various modiﬁcations of
timoprazole and eventually found that the introduction of ﬂuorinated
substituents, such as a triﬂuoroethoxy group, to timoprazole markedly
improved the antiulcer properties of the compound, which resulted in
the discovery of lansoprazole (Kubo et al., 1990). Substituted benzimid-
azoles such as pantoprazole and rabeprazole were also developed.
Tenatoprazole has an imidazopyridine ring instead of a benzimidazole
ring and a plasma half-life of about 7 h, which is longer than that of
benzimidazole-based PPIs (Sachs et al., 2006). However, tenatoprazole
has not yet been approved for marketing and sale. Omeprazole is a
racemic mixture of two enantiomers, R-omeprazole and S-omeprazole,
that show different afﬁnities for cytochrome P450 (CYP) enzymes. The
plasma level of S-omeprazole (esomeprazole) is better than R-
omeprazole because the R-enantiomer is more sensitive to CYP2C19
than S-omeprazole (Abelö et al., 2000; Andersson et al., 2001). Like omep-
razole, lansoprazole is also a racemate, though its R- and S-enantiomers
were shown to have equal pharmacological activity (Nagaya et al.,
1991). However, unlike omeprazole, the R-enantiomer (dexlansoprazole)
of lansoprazole was shown to be less sensitive to CYP enzymes. A novel
dual release formulation of dexlansoprazole consisting of a normal enteric
coating release at pH 5.5 (pH in upper intestine) and a coating release at
pH6.75 (pH in lower intestine) extended the duration of dexlansoprazole
in the blood (Emerson & Marzella, 2010). Dexlansoprazole also allows
ﬂexible dosing such that administration of the drug could be independent
of timing of food intake (Lee et al., 2010). In a clinical study, 60mg of this
dual release formulation of dexlansoprazole resulted in a higher
intragastric pH than 40 mg of esomeprazole (Kukulka et al., 2011). The
canaliculus of the parietal cell is the only membrane-enclosed space in
the body with a pH below 4.0. All PPIs are lipophilic and weak bases
with pKa values of 3.8 to 5.0. They easily penetrate cell membranes and
are accumulated in the highly acidic parietal cell canaliculi as a result of
protonation of the pyridine moiety, which renders them less permeable
(Sachs et al., 2014). A second protonation of the benzimidazole ring
causes a chemical rearrangement involving nucleophilic attack of the pyr-
idine ring, producing a planar cationic sulfenic acid (Lindberg et al., 1986;
Nagaya et al., 1989). This sulfenamide form produced by dehydration of
the sulfenic acid is the active form of PPIs. It reacts with cysteine sulfhy-
dryls on H+,K+-ATPase to form covalent disulﬁde bonds that inhibit
pump activity.
PPIs are weak bases with a pKa value of around 4.0 that allows their
selective accumulation in the secretory canaliculus of the parietal cell.
Whole body autoradiography of a mouse injected intravenously with
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eral hours labeling was found only in the stomach (Helander et al.,
1985). Higher magniﬁcation showed that labeling was present only in
parietal cells (Scott et al., 1994), and a radioautographic study of 3H-
labeled lansoprazole revealed that most silver grains were found in
the cytoplasmic canaliculi (Sekiguchi et al., 1992). These ﬁndings sug-
gest that lansoprazole accumulates in parietal cells, and its binding is co-
valent. The binding location of radioactive PPIs on H+,K+-ATPase
revealed one or more cysteine(s) that were critical for inhibition of en-
zyme activity. Full inhibition was obtained by lansoprazole labeling of
Cys321, Cys813 or Cys822, and Cys892 (Sachs et al., 1993), omeprazole
labeling of Cys813 or Cys892 and slight labeling of Cys892 (Besancon
et al., 1993), and pantoprazole labeling of Cys813 and Cys822 (Shin
et al., 1994). All active forms of all PPIs reactwith Cys813,which is locat-
ed in a luminal vestibule of H+,K+-ATPase. This reaction results in cova-
lent inhibition of the enzyme via formation of a disulﬁde bond that
stabilizes the enzyme in its E2 conformation. The covalent binding of
PPIs with H+,K+-ATPase allows a duration of action far longer than
their plasma half-life. PPIs aremetabolized by the CYP system. The prin-
cipal enzyme of their metabolism is CYP2C19, with CYP3A4 also being
involved. The CYP2C19 gene is mutated in approximately 3% of Cauca-
sians and 13% to 22% of East Asians, resulting in PPIs having relatively
poor clearance (Furuta et al., 2005). CYP2C19 genotypes are classiﬁed
into three groups: homozygous extensivemetabolizer (HomEM), hetero-
zygous EM (HetEM), and poor metabolizer (PM). Plasma PPI levels and
intragastric pHs during PPI treatment are lowest in the HomEM group,
higher in the HetEM, and highest in the PM group. These CYP2C19 poly-
morphisms inﬂuence the pharmacokinetics and pharmacodynamics of
PPIs (Shirai et al., 2002). CYP2C19 genotype is a crucial factor in determin-
ing the efﬁcacy of H. pylori eradication in patients taking PPI-based triple
therapies (Kuo et al., 2014). Clopidogrel is an antiplatelet agent and inac-
tive prodrug that ismainly converted to its activemetabolite via CYP2C19.
Because of this, the Food and Drug Administration has warned against
using certain PPIs in patients receiving clopidogrel. Lansoprazole,
dexlansoprazole, pantoprazole-Na, and rabeprazole appear to be associat-
ed with lower incidences of drug interactions compared to omeprazole
and esomeprazole (Frelinger et al., 2012; Wedemeyer & Blume, 2014).
However, a randomized controlled trial that compared clopidogrel alone
with combination therapy of clopidogrel and omeprazole found no in-
crease in adverse cardiovascular outcomes, and observed that PPI co-
therapy reduced the risk of new adverse gastrointestinal outcomes
(Bhatt et al., 2010).
Although PPIs have been very successful and effective, they also pos-
sess a number of limitations, such as less than complete gastric acid sup-
pression (especially at night), interpatient variability in efﬁcacy due to
CYP2C19 metabolism, and the inconvenience of requiring mealtime
dosing to ensure adequate levels of the drug during periods of H+,K+-
ATPase activity. In addition, PPIs are slow to achieve steady state inhibi-
tion of gastric acid secretion, typically taking 3 to 5 days to achievemax-
imum inhibition (Piche & Galmiche, 2005; Sachs et al., 2006). The slow
onset of action of PPIs results from the continuous switching of H+,K+-
ATPase from an inactive to active state, the need for PPI accumulation
and activation in the parietal cell, and the short plasma half-life (about
1.5 h) of PPIs (Hatlebakk & Berstad, 1996; Sachs, 2001). A PPI can only
inhibit H+,K+-ATPase that is actively secreting at the surface of the se-
cretory canaliculus of the parietal cell. Although any H+,K+-ATPase
with a covalently bound PPI will remain inactive unless inhibition is re-
versed by a cellular reducing agent such as glutathione, newly synthe-
sized H+,K+-ATPase or those activated after the plasma concentration
of the PPI has fallen below threshold will not be inhibited. The short
plasma half-life of PPIs allows rapid restoration of gastric acid secretion
by uninhibited, restored, or newproton pumps. Consequently, for GERD
patients, more complete and faster relief of symptoms is still needed
(Kleinman et al., 2002). In about two thirds of symptomatic GERD pa-
tients, reﬂux symptoms are not adequately controlled by an initial
dose of PPI, with nearly 50% of patients still suffering from symptoms3 days later (Yuan et al., 2008;Hunt& Scarpignato, 2015). Approximate-
ly one-third of GERD patients report persistent symptoms and are
dissatisﬁed with PPI therapy (Chey et al., 2010). One strategy to im-
prove PPI therapy has been to prolong the plasma dwell time of PPIs.
Alevium (AGN201904-Z), made by Alevium Pharmaceuticals, is a
prodrug form of omeprazole that is slowly absorbed throughout the in-
testine, resulting in a longer plasma dwell time compared to other PPIs.
Alevium at 600 mg showed a more prolonged acid-suppressive effect
than esomeprazole at 40 mg in healthy volunteers (Hunt et al., 2008),
though there has been no further clinical development of this com-
pound. Another strategy to prolong blockage of H+,K+-ATPase was to
develop drugs more resistant to metabolism, such as esomeprazole
and dexlansoprazole. However, despite several years of extensive re-
search and advances in our understanding of PPIs, their limitations
still remain (Sachs et al., 2010).While PPI limitations are mainly related
to their shared mechanism of action, these new drugs represented a
measurable but only incremental advance in control over gastric acid
secretion compared to conventional PPIs, so it was logical that other po-
tential approaches would be considered. A more innovative approach
has been the development of potassium-competitive acid blockers
(Andersson & Carlsson, 2005).
5. Potassium-competitive acid blockers
5.1. Development of potassium-competitive acid blockers
In the early 1980s, an imidazopyridine compound, SCH28080, was
developed by Schering-Plough that inhibited gastric acid secretion in
animals and humans (Ene et al., 1982; Chiu et al., 1983). SCH28080
inhibited the acid response to histamine, high K+, methacholine, and
cyclic AMP. Kinetic studies indicated competitive inhibition of H+,K+-
ATPase by SCH28080 with respect to K+, suggesting a competitive in-
teraction with the high afﬁnity K+-site of H+,K+-ATPase (Beil et al.,
1986). However, clinical development of SCH28080 was stopped
because repeated administration caused hepatic toxicity. This initiated
studies of a series of SCH28080 derivatives. Imidazopyridine derivatives
(e.g., linaprazan and BY841), imidazonaphthyridine derivatives
(e.g., soraprazan), imidazothienopyridines (e.g., SPI-447), quinolone
derivatives (e.g., SK&F96067 and SK&F97574), pyrrolopyridazine deriv-
atives (e.g., CS-526), pyrimidine derivatives (e.g., revaprazan) and pyr-
role derivatives (e.g., vonoprazan) were developed (Wallmark et al.,
1987; Keeling et al., 1991; Wurst & Hartmann, 1996; Tsukimi et al.,
2000; Park et al., 2003; Gedda et al., 2007; Hori et al., 2010). Such
compounds that compete with K+ binding and inhibit gastric acid
secretion are called potassium-competitive acid blockers (P-CABs),
or acid pump antagonists. The chemical structures of SCH28080,
soraprazan, revaprazan, linaprazan (AZD0865), and vonoprazan (TAK-
438) are shown in Fig. 2. Among these compounds, revaprazan and
vonoprazan were developed for clinical use, approved, and now used
as therapeutics for the treatment of ARDs. Revaprazan was launched
in South Korea in 2007 by Yuhan Corporation for the treatment of
duodenal ulcer, gastric ulcer and gastritis, and is also available in India.
Vonoprazan was ﬁrst launched in Japan in 2015 by Takeda Pharmaceu-
ticals for the treatment of gastric ulcer, duodenal ulcer, erosive
esophagitis, prevention of low dose aspirin- or NSAID-induced ulcer re-
currence, and as an adjunct for H. pylori eradication.
The development of other P-CABs has since been discontinued, and
of these discontinued compounds only the clinical trial results for
linaprazan have been published (Kahrilas et al., 2007; Dent et al.,
2008). Linaprazan provided similar efﬁcacy to esomeprazole, but raised
liver transaminase in a dose-dependent fashion. The clinical develop-
ment of linaprazan was discontinued since it did not provide clinical
beneﬁt over esomeprazole in patient management (Maradey-Romero
& Fass, 2014).
RQ-4,made byRaQualia Pharma, is currently in clinical development
in Korea. The chemical structure of RQ-4 has not been published.
SCH28080 Soraprazan Revaprazan 
(Schering-Plough) (Nycomed) (Yuhan) 
Linaprazan Vonoprazan 
(AstraZeneca) (Takeda) 
Fig. 2. Chemical structures of potassium-competitive acid blockers.
Fig. 3. Ribbon representation of H+,K+-ATPase and the vonoprazan binding site (TAK-
438). The membrane position is indicated with yellow lines. TM1, dark blue; TM2, cyan;
TM3, light green; TM4, green-blue; TM5, light yellow; TM6, dark yellow; TM7, light
brown; TM8, dark brown; TM9, light red; TM10, dark red. The position of the potassium
ion binding site is close to the middle of the membrane (ball and stick), and vonoprazan
(TAK-438; space ﬁlling in light blue) binds ~10 Å from the ion binding site in a cavity
bounded by M1, TM2, TM4, and the TM5-TM6 loop. Reproduced from Shin et al. (2011)
with permission from J Pharmacol Exp Ther.
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P-CABs are weak bases, and SCH28080, linaprazan and vonoprazan
have pKa values of 5.6, 6.1, and 9.3, respectively (Keeling et al., 1988;
Gedda et al., 2007; Hori et al., 2010). Linaprazan inhibited K+-
stimulated H+,K+-ATPase with an IC50 of 1.0 μM at pH 7.4, but was 8
times more potent at pH 6.4. The theoretical percent of protonated
linaprazan is about 33% at pH 6.4 and less than 5% at pH 7.4. The inhib-
itory effect of SCH28080 is also weaker in neutral conditions (IC50 =
0.14 μM at pH 6.5 vs. IC50 = 2.5 μM at pH 7.4). These results suggest
that protonated forms of P-CABs inhibit H+,K+-ATPase. Linaprazan
inhibited more potently in ion-tight vesicles than in ion-leaky vesicles,
suggesting this agent concentrates in regions of low pH and has a luminal
site of action (Gedda et al., 2007). As the pKa value of vonoprazan is 9.3,
most of this compound should be protonated instantly and exert potent
inhibition (IC50 = 19 nM at pH 6.5, IC50 = 28 nM at pH 7.5; Hori et al.,
2010). Because protonated compounds are less membrane permeable
than non-ionic compounds, protonated P-CABs are thought to concen-
trate in the acidic secretory canaliculi of parietal cells where they pro-
duce H+,K+-ATPase inhibition. In rats administered vonoprazan, the
stomach concentration of vonoprazan was much higher than the plas-
ma concentration following oral administration of [14C]vonoprazan
(Hori et al., 2011), and following intravenous administration [-
3H]vonoprazan selectively accumulated in acid-secreting gastric parie-
tal cells in the mucosa of the rat stomach (Matsukawa et al., 2016). In
Heidenhain pouch dogs, the concentration of linaprazan in gastric
juice exceeded the plasma concentration at 2 h after administration,
and while the concentration of linaprazan was detectable in gastric
juice 24 h after administration, it was undetectable in plasma in most
animals (Holstein et al., 2004a, 2004b). These ﬁndings indicate that
after entering into acidic secretory canaliculi, P-CABs are instantly pro-
tonated and accumulate at much higher concentrations than PPIs, and
inhibit acid secretion by binding with H+,K+-ATPase ionically and by
competingwith K+ (Matsukawa et al., 2011). Scott et al. (2015) recent-
ly demonstrated that [14C]-vonoprazan binds equally to resting andstimulated rabbit gastric glands, while autoradiographic analysis
showed no difference in labeling between resting and stimulated gas-
tric parietal cells, indicating that vonoprazan binds selectively to the pa-
rietal cell independent of acid secretion and vonoprazan labels both
active and inactiveH+,K+-ATPase. This is in sharp contrast to the results
obtained for omeprazole, where binding of omeprazole to parietal cells
in rabbit gastric glands increased when acid secretion was stimulated
and decreased with inhibition of secretion (Scott et al., 1993). Accumu-
lation and acid activation are required for the action of PPIs, but are not
required for the action of vonoprazan.
P-CABs bind selectively to the E2-P form of H+,K+-ATPase, a mecha-
nism supported by the ﬁnding that SCH28080 binding afﬁnity increased
approximately 10-fold in the presence of ATP (Keeling et al., 1989;
Mendlein & Sachs, 1990). SCH28080 inhibits K+-stimulated ATPase ac-
tivity by competing with K+ for binding to E2-P and blocking K+-
stimulated dephosphorylation. The binding sites of SCH28080 and
vonoprazan have been investigated thoroughly using a H+,K+-ATPase
homology model based on the crystallographic structure of Na+,K+-
ATPase (Shin et al., 2011; Scott et al., 2015). Vonoprazan gains access
to its binding site from the lumen through a wide entry space bounded
by the TM1/TM2 and TM5/TM6 loops and the extracytoplasmic ends of
TM4, TM8, and TM9. Following entry, this space closes and vonoprazan
is trapped in the vestibule (Fig. 3). The positively charged N-methyl-
amino side chain on vonoprazan is located within 2.4 Å of Glu795,
producing strong hydrogen bonding and charge interaction with the
K+ site at Glu795, which is in contrast with the binding characteristics
of SCH28080 and other P-CABs. Another divergence from the predicted
binding of vonoprazan to the vestibule in H+,K+-ATPase is the
suggested hydrogen bonding between Tyr799 and the sulfone of
vonoprazan (Shin et al., 2011). Improved binding site models have re-
cently suggested that vonoprazan is largely occluded by H+,K+-ATPase
after binding, and predict that vonoprazan is buried in a greater surface
area and occupies a larger percentage of its surface area than SCH28080.
Vonoprazan exit into the lumen is hindered by asp137 and asn138 in
the loop between TM1 and TM2, which presents an electrostatic barrier
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These binding characteristics could explain the very slow dissociation of
vonoprazan fromH+,K+-ATPase, and its more effective and longer action
compared to other P-CABs.
5.3. Pharmacokinetics of potassium-competitive acid blockers
In studies conducted in healthy subjects in Japan and the UK,
vonoprazan at 1 to 120 mg in Japan and 10 to 40 mg in the UK resulted
in rapid peak plasma concentration (median Tmax of up to 2 h), and an
estimated half-life (T1/2) of up to 9 h (Sakurai et al., 2015b). In repeated
administration studies in Japanese and non-Japanese subjects, the me-
dian Tmax of vonoprazan at 10 to 40 mg under fasting conditions was
1.5 h, with T1/2 ranging from 5.7 to 8.8 h (Jenkins et al., 2015). The
mean accumulation index was 1.1 to 1.2 in both studies, with only
minor vonoprazan accumulation during repeated dosing. Pharmacoki-
netic parameters for each dose were similar on Day 1 and 7. Values of
Cmax and AUC0–48 h following administration of a single vonoprazan
20mgwere almost the same under fasting and fed conditions, showing
that bioavailabilitywas not affected by food intake. An exploratory anal-
ysis of Japanese data compared dose-normalized AUC0-tau on Day 7 be-
tween different CYP2C19 genotypes and found no correlation between
CYP2C19 genotype (*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3) and AUC0-tau.
After oral administration of [14C]vonoprazan in rats at 2 mg/kg,
vonoprazan concentrations in plasma reached 17 ng/mL (Cmax) at 0.3 h
(Tmax). Vonoprazan concentration in plasma decreased with a T1/2 of
1.3 h and the AUC0–24 h of vonoprazan was 27 ng·h/mL. The bioavailabil-
ity of vonoprazan after oral administration in rats was 10%. Oral adminis-
tration of vonoprazan at 0.3 mg/kg in dogs indicated that Tmax, Cmax, T1/2
and AUC0–24 h were 1.0 h, 30 ng/mL, 1.1 h, and 68 ng·h/mL, respectively.
The bioavailability of vonoprazan after oral administration in dogs was
52% (Hori et al., 2011).
Repeated administration of revaprazan in healthy males resulted in
peak plasma concentrations at 1.7 to 1.8 h after a single dose adminis-
tered on Day 1 (100 to 200 mg), which declined with a T1/2 of 2.2 to
2.4 h (Kim et al., 2010). The concentration-time proﬁles and pharmaco-
kinetic characteristics of revaprazan following repeated administration
(on Day 7) were similar to those observed after the ﬁrst dose on Day
1. Another study of revaprazan administration to healthy volunteers
showed linear pharmacokinetic characteristics and little accumulation
after multiple administrations (Yu et al., 2004). Single oral doses of
linaprazan (0.08 to 4.0 mg/kg) in healthy subjects also resulted in a
rapid increase in plasma concentration, with a dose-proportional in-
crease in AUC and Cmax (Nilsson et al., 2005).
These ﬁndings indicate that P-CABs rapidly achieve peak plasma
concentrations, partly because the compounds are acid-stable and can
be administered as immediate-release formulations.
5.4. Pharmacodynamics of potassium-competitive acid blockers
The potent and long-lasting antisecretory effect of vonoprazan has
been observed in both rats and dogs. Oral administration of vonoprazan
at 4 mg/kg completely inhibited basal and 2-deoxy-D-glucose-stimulat-
ed gastric acid secretion in rats, and exhibited stronger inhibitory effect
than lansoprazole. Vonoprazan increased the pH of gastric perfusate
under histamine stimulation in rats to a higher value than lansoprazole
or SCH28080, and this effect persisted for longer with vonoprazan than
lansoprazole or SCH28080 (Hori et al., 2010). Vonoprazanalso exhibited
a more potent and longer-lasting inhibitory effect compared to
lansoprazole in dogs (Hori et al., 2011). The signiﬁcant antisecretory ef-
fect of vonoprazan in rats was not affected by cimetidine pretreatment;
a result that is in contrast to lansoprazole, which failed to demonstrate
an antisecretory effect after cimetidine pretreatment. This ﬁnding sug-
gests the inhibitory effect of vonoprazan on gastric acid secretion is un-
affected by gastric acid secretory state, while the inhibitory effect of PPIson gastric acid secretion is altered by gastric acid secretory state (De
Graef & Woussen-Colle, 1986).
The pharmacodynamic effects of vonoprazan administered at 10 to
40 mg for 7 days were examined in Japanese and non-Japanese (UK)
healthy subjects (Fig. 4; Jenkins et al., 2015). On day 1, there was a
dose-dependent increase in mean intragastric pH, and the onset of
this pH increase was rapid. At all dose levels, mean intragastric pH
was N4.0 by 4 h after the ﬁrst dose. The rapidity of onset was dose-
dependent, with higher doses clearly having an earlier effect on pH
compared to lower doses. The normal tendency for intragastric pH to
fall during nighttime hours was also attenuated by vonoprazan in a
strongly dose-dependent fashion. The mean intragastric pH-time pro-
ﬁles onDay 7 of repeated vonoprazan dosing showed that pH values be-
fore dosing and during the ﬁrst 4 h after dosing were higher than at the
corresponding time points on Day 1, and this increase in pHwas strong-
ly dose-dependent. The 24-h pH N4 and pH N5 holding time ratio (HTR)
also increased dose-dependently and similarly in both studies (Table 1).
Mean pH N4 and pH N5 HTRs after the 40mg dose on Day 1 were 85.3%
and 78.3% respectively (Japan) and 85.6% and 73.1% respectively (UK).
Corresponding results for mean pH N4 and pH N5 HTRs on Day 7 were
100% and 98.6% respectively (Japan) and 93.2% and 85.0% respectively
(UK). The acid-inhibitory effect of vonoprazan 20 mg administered
daily for 7 days was compared with that of esomeprazole 20 mg or
rabeprazole 10 mg in healthy Japanese subjects with the CYP2C19
extensive metabolizer genotype, and showed vonoprazan exhibited a
signiﬁcantly greater acid-inhibitory effect than esomeprazole and
rabeprazole on both Day 1 and Day 7 (Fig. 5; Sakurai et al., 2015a).
Kagami et al. (2016) also reported that mean pH N4 and pH N5 HTRs
with single daily dosing of vonoprazan 20 mg were higher than those
with esomeprazole 20 mg administered twice daily to a mixed
CYP2C19 genotype group. The pharmacodynamic proﬁle of vonoprazan
therefore suggests that it might have advantages over existing acid-
suppressing drugs that include maximum efﬁcacy after the ﬁrst dose,
potency, prevention of nocturnal acid breakthrough (intragastric pH
b4 for at least 60 continuous minutes during nighttime), reduction in
nighttime gastric acidity, and the ability to dose at any time regardless
of meals.
Pharmacodynamic studies of someother P-CABs have also been con-
ducted at the developmental stage. Revaprazan administered at 100,
150 and 200 mg daily for 7 days increased pH N4 HTR in a dose-
dependent manner in healthy volunteers. The mean pH N4 HTRs for
revaprazan 200 mg in H. pylori-negative subjects were 28.1% at Day 1
and 34.2% at Day 7 (Kim et al., 2010), indicating revaprazan has aweak-
er acid suppressive effect than PPIs. After single doses of linaprazan (0.5
to 1.0 mg/kg) in healthy subjects, almost complete inhibition of acid
production occurredwithin 1 h of dosing and continued for the duration
of observation (15 h) at doses of 0.8 mg/kg and above (Nilsson et al.,
2005). The pharmacodynamic data for vonoprazan, revaprazan and
linaprazan suggest that themagnitude and duration of the inhibitory ef-
fect of P-CABs aremainly determined by dose, pKa, and plasma half-life.
5.5. Efﬁcacy of potassium-competitive acid blockers
compared with PPIs in patients with acid-related diseases
Phase 3 clinical studies of vonoprazan versus lansoprazole have been
conducted in Japan to investigate the efﬁcacy and safety of vonoprazan
in the healing and maintenance of erosive esophagitis, prevention of
aspirin- or NSAID-induced ulcer recurrence, gastric ulcer, duodenal
ulcer, and H. pylori eradication. This section highlights clinical results
for vonoprazan and lansoprazole in healing erosive esophagitis and
H. pylori eradication to clarify the positioning of P-CABs in ARD
management.
5.5.1. Healing of erosive esophagitis
In a phase 2 clinical study, vonoprazan or lansoprazole was adminis-
tered to a total of 732 patients with erosive esophagitis. The results are
Fig. 4.Mean intragastric pH on Day 1 in healthy male subjects after administering vonoprazan (TAK-438) 10–40 mg after overnight fasting in Japanese (left panel) and UK (right panel)
studies (Japan N = 60; UK N = 48). Reproduced from Jenkins et al. (2015) with permission from Alim Pharmacol Ther.
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non-inferior to lansoprazole 30 mg (P b 0.004) (Ashida et al., 2015). In
a phase 3 clinical study, a total of 409 patients with LA grades A–D
esophagitis were randomized to vonoprazan 20 mg or lansoprazole
30mg once daily for 8 weeks, and healing of esophagitis was examined
by endoscopy at 2, 4 and 8 weeks. The healing rate at 8 weeks, the pri-
mary endpoint of the study, was 99.0% in the vonoprazan group and
95.5% in the lansoprazole group. In post-hoc analyses, stratiﬁcation ac-
cording to LA grade of esophagitis at baseline revealed a signiﬁcant dif-
ference in the healing rate between vonoprazan and lansoprazole for
grade C/D patients; the healing rates at 8 weeks were 98.7% and
87.5%, respectively. The secondary endpoint was healing rate at
4 weeks, which was 96.6% in the vonoprazan group and 92.5% in the
lansoprazole group. The healing rate for vonoprazan 20 mg at 4 weeks
was almost identical to that for lansoprazole 30 mg at 8 weeks. The
healing rate after 2 weeks treatment in the vonoprazan group (90.7%)Table 1
Dose–response relationship for mean 24-h intragastric pH N4 and N5 holding time ratio
[HTR (%)] during 24-h dosing interval in healthy subjects who received vonoprazan 10–
40 mg once daily at a ﬁxed dose level for 7 consecutive days in Japanese and UK studies
(reference: Jenkins et al., 2015).
Placebo Vonoprazan
10 mg 20 mg 40 mg
Japanese study
n 15 9 9 9
24-h pH N 4 HTR (%)
Day 1 8.3 ± 4.0 38.4 ± 22.3 63.3 ± 17.9 85.3 ± 8.3
Day 7 5.6 ± 3.5 63.3 ± 8.7 83.4 ± 16.7 100.0 ± 0.0
24-h pH N 5 HTR (%)
Day 1 3.7 ± 2.4 25.1 ± 19.0 53.5 ± 21.5 78.3 ± 10.6
Day 7 1.5 ± 1.5 52.6 ± 10.7 73.2 ± 18.9 98.6 ± 2.0
UK study
n 12 9 9 9
24-h pH N 4 HTR (%)
Day 1 6.2 ± 3.2 43.1 ± 21.2 62.7 ± 16.8 85.6 ± 7.4
Day 7 6.5 ± 4.5 60.2 ± 19.1 85.2 ± 12.3 93.2 ± 10.5
24-h pH N 5 HTR (%)
Day 1 2.6 ± 2.0 31.5 ± 20.8 49.2 ± 19.9 73.1 ± 11.0
Day 7 3.2 ± 3.2 49.5 ± 15.8 78.6 ± 14.0 85.0 ± 21.7
All data are represented as means ± S.D.was also higher than that observed in the lansoprazole group (81.9%,
P b 0.0132 [Fisher's exact test; Post-hoc analysis]; Ashida et al., 2016).
5.5.2. Helicobacter pylori eradication
To compare ﬁrst line H. pylori eradication therapies, a total of 650
H. pylori-positive patients with cicatrized gastric or duodenal ulcers
were randomized to triple therapywith either vonoprazan (vonoprazan
20 mg, amoxicillin 750 mg, clarithromycin 200 mg or 400 mg twice
daily for 7 days) or to triple therapy with lansoprazole (lansoprazole
30 mg, amoxicillin 750 mg, clarithromycin 200 mg or 400 mg twice
daily for 7 days). Fifty of 101 subjects in whom eradication with a ﬁrst
line therapy failed received a 7-day course of second line therapy
(vonoprazan 20 mg, amoxicillin 750 mg, metronidazole 250 mg
twice daily). The ﬁrst line H. pylori eradication rate was 92.6% in
the vonoprazan group and 75.9% in the lansoprazole group. Non-
inferiority of vonoprazan to lansoprazole was veriﬁed. A post-hoc anal-
ysis subsequently indicated that vonoprazan performed signiﬁcantly
better than lansoprazole as a component in the ﬁrst line therapy. Nota-
bly, the H. pylori eradication rate was signiﬁcantly higher in the
vonoprazan group compared with the lansoprazole group in the sub-
jects with clarithromycin resistance (82.0% and 40.0%, respectively;
pre-planned grouping and post-hoc statistical test). Second line therapy
with vonoprazan resulted in eradication rate of 98% (Murakami et al.,
2016).
Only one report on revaprazan efﬁcacy could be found in the public
domain. This report compared revaprazan with omeprazole for the
healing of gastric ulcer in South Korean patients. Two hundred and
ninety-two patients were randomized to 4 to 8 weeks of treatment
with either revaprazan 200 mg or omeprazole 20 mg. ITT analysis re-
vealed similar cumulative healing rates; 93.0% for revaprazan treatment
and 89.6% for omeprazole treatment (Chang et al., 2007).
Comparative studies of linaprazan and esomeprazole have been con-
ducted in the healing of erosive esophagitis and the treatment of pa-
tients with nonerosive reﬂux disease. Nonerosive reﬂux disease is
deﬁned as presentation of typical GERD symptoms such as heartburn
or regurgitation in the absence of visible esophageal mucosal break,
while erosive esophagitis is deﬁned as an endoscopically-conﬁrmed
esophageal mucosal break. After 4 weeks of treatment, erosive esopha-
gitis healing rates were 76.9%, 78.2%, 81.1% and 81.9% in linaprazan 25,
50, 75 mg and esomeprazole 40 mg treatment groups, respectively.
Fig. 5. Time courses of intragastric pH over 24 h for (a) vonoprazan 20mg and (b) esomeprazole 20mg onDays 1 and 7 (n= 10). The pH data fromDay-2 to Day-1 were used as baseline
data for both treatments. All study drugs were administered at time 0 (as a rule, 9:00 AM) onDays 1–7. The triangles indicate the timing of meals. Reproduced from Sakurai et al. (2015a)
with permission from Alim Pharmacol Ther.
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ments (Kahrilas et al., 2007). No signiﬁcant differences were observed
between linaprazan 25, 50, 75mg and esomeprazole 20mg in the treat-
ment of patientswith nonerosive reﬂux disease (Dent et al., 2008). Even
though linaprazan resulted in a faster onset of acid inhibition, it did not
provide clinical beneﬁt over esomeprazole in the management of pa-
tients with erosive esophagitis or nonerosive reﬂux disease, and its de-
velopment was discontinued (Sachs et al., 2010; Hunt & Scarpignato,
2015).
5.6. Safety of potassium-competitive acid blockers
In a clinical phase 3 study of treatment of patients with erosive
esophagitis in Japan, the incidences of treatment-emergent adverse
events with vonoprazan 20mg were similar to those with lansoprazole
30 mg; 22.2% in the vonoprazan group vs. 22.3% in the lansoprazole
group (Ashida et al., 2016). In a study assessing 24-week maintenance
treatment for healed erosive esophagitis, the overall incidence of
treatment-emergent adverse events was comparable between the
treatment groups; 54.0% in the vonoprazan 10 mg group, 58.8% in the
vonoprazan 20 mg group, and 51.2% in the lansoprazole 15 mg group
(Umegaki et al., 2014). Importantly, vonoprazan did not increase
serum alanine aminotransferase (ALT), aspartate aminotransferase
(AST), or total bilirubin levels, probably because its chemical structure
differs signiﬁcantly from other P-CABs such as linaprazan. Greater in-
creases in serum gastrin and pepsinogen I and II were observed during
treatment with vonoprazan than with lansoprazole, probably as a con-
sequence of greater inhibition of gastric acid secretion by vonoprazan
compared with lansoprazole (Ashida et al., 2015).
In a clinical study of linaprazan (25, 50 and 75mg) and esomeprazole
20mg for the treatment of nonerosive reﬂux disease, the incidence of ad-
verse events was similar across treatment groups, and headache was the
only adverse event that occurred inmore than 5% of patients in any groupTable 2
Proportion of healed erosive esophagitis subjects as shown by endoscopy at week 4 (reference
LA grade Lansoprazole 30 mg Vonoprazan
5 mg
Overall 123/132 (93.2) 132/143 (92.3)
A/B 83/86 (96.5) 84/88 (95.5)
C/D 40/46 (87.0) 48/55 (87.3)
Data are represented as numbers of subjects with percentages in parentheses.(Dent et al., 2008). In the linaprazan treatment groups, increases in liver
transaminases were observed more commonly at higher doses, and for
the most part these increases developed after 4 weeks of treatment.
SCH28080 shares the imidazopyridine ring structure of linaprazan and
has been shown to affect the liver (Parsons & Keeling, 2005). AR-
H047108, an imidazopyridine-related compound of linaprazan, is report-
ed to cause hepatotoxicity in dogs (Berg et al., 2008). These results sug-
gest a possible chemical class effect of imidazopyridine compounds that
causes liver toxicity.
6. Summary
During the past 40 years, treatment of PUDhas changed dramatically
from diet and surgery to H2RAs, which were followed by PPIs. H2RAs
were the ﬁrst effective pharmacological treatment of PUD, but their rel-
atively weak efﬁcacy for GERD and the development of patient toler-
ance required the development of more effective acid suppressants.
Since the introduction of PPIs, outcomes in ARD therapy have improved
dramatically, and now PPIs are the ﬁrst choice of treatment of ARDs.
However, there are still areas of medical need in acid control that are
not met by PPIs, because 1) PPIs produce insufﬁcient gastric acid sup-
pression, especially at night, 2) PPIs are slow to achieve steady state in-
hibition of gastric acid secretion, typically taking 3 to 5 days to achieve
maximum inhibition of acid secretion, 3) there are large interindividual
variations in efﬁcacy due to CYP2C19metabolism, and 4)mealtime dos-
ing is required to ensure adequate levels of the drug during periods of
H+,K+-ATPase activation.
The discovery of H. pylori and its causative role in PUD, gastritis and
gastric cancermade its eradication the standard of care for patientswith
H. pylori. The recent increasing prevalence of antibiotic resistance and
decrease in eradication rates provided by the regimens that include
PPIs necessitates the development of more potent gastric acid suppres-
sants. P-CABs have several advantages over PPIs that are translated into: Ashida et al., 2015).
10 mg 20 mg 40 mg
123/133 (92.5) 136/144 (94.4) 130/134 (97.0)
85/89 (95.5) 86/94 (91.5) 82/84 (97.6)
38/44 (86.4) 50/50 (100) 48/50 (96.0)
20 N. Inatomi et al. / Pharmacology & Therapeutics 168 (2016) 12–22clinical beneﬁts in the treatment of erosive esophagitis and H. pylori
eradication: 1) P-CABs rapidly achieve therapeutic plasma levels and
provide almost complete inhibition of gastric acid secretion from the
ﬁrst dose; 2) there is much less interindividual variation in P-CAB me-
tabolism and efﬁcacy due to no or minimal involvement of CYP2C19
metabolism; 3) P-CABs action is independent of secretory state; 4) P-
CABs are acid stable and do not require an enteric coating formulation.
Since the development of SCH28080, many pharmaceutical companies
have attempted to develop P-CABs. Revaprazan is only used in South
Korea and India, and has not been developed for clinical use in other
countries. The clinical development of other compounds, such as
soraprazan, CS526 and linaprazan, has been discontinued probably be-
cause these agents could not demonstrate effectiveness superior to
PPIs and produced signs of hepatic toxicity.
Vonoprazan, recently approved in Japan, has a different chemical
structure and a higher pKa value compared to other P-CABs, and has
produced effective and longer-lasting acid suppression in both animals
and humans. In clinical studies in Japan, post-hoc analyses indicated
that vonoprazan was more effective than lansoprazole in the healing
of reﬂux esophagitis and H. pylori eradication. Vonoprazan has also
been shown to be safe and well tolerated in clinical studies, with an in-
cidence of adverse events similar to that of lansoprazole. Because of
their enhanced effectiveness and good tolerability, it is likely that P-
CABs, such as vonoprazan, will further improve the treatment of ARD.
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